If phase 3 results remain positive, regulatory submissions may begin in 2026, meaning orforglipron could become available in late 2026 or 2027, depending on MHRA and NICE approval timelines
From the moment I walked in, the vibe was so welcoming and luxurious
I dont recommend skipping or lowering your dose
For GLP-1 users looking to support their protein and electrolyte intake, Arrae Clear Protein+ offers a convenient way to address both
Semaglutide, a GLP-1RA, mitigates seizure severity and cognitive impairment through the inhibition of the lipopolysaccharide (LPS)- and nigericin-induced NLRP3 inflammasome pathway, reducing lactate dehydrogenase (LDH) release by microglial cells [53]
Shima Hadidchi, MD , provides guidance on qualifying for Semaglutide GLP-1 weight loss, generally recommended for patients with a BMI of 30+ or 27+ with weight-related health conditions